Schering-Plough Indonesia expects 20% profit rise
Schering-Plough Indonesia expects 20% profit rise
JAKARTA (JP): The manufacturer of pharmaceutical products, PT
Schering-Plough Indonesia, expects its profits to rise 20 percent
this year, company spokesman Tjiptono Darmadji said yesterday.
Tjiptono said the profit rise would result from a price rise
of between 8 percent and 9 percent and increased sales.
He did not say how much he expected sales to rise.
The company reported a 33 percent profit growth to Rp 7.3
billion for 1995.
"Overall, our company is in good financial shape, meaning that
our performance has improved steadily over the years," he said.
Schering-Plough Indonesia, a joint venture involving Schering
Corporation of the United States, is one of nine chemical
companies listed on the Jakarta Stock Exchange.
The company's annual earning per share increased to Rp 2,093
(87 U.S. cents) last year from Rp 2,040 in 1995.
Tjiptono said the company's sales had continuously increased
from Rp 25.18 billion in 1993 to Rp 30.16 billion in 1994 and Rp
39.74 billion in 1995.
Special exports to Russia caused an 112 percent increase in
the company's export earnings to Rp 8.43 billion in 1995 from Rp
3.97 billion in 1994.
Between January and November last year, it made Rp 3.9 billion
in export earnings, around 10 percent of its total sales of Rp
35.23 billion.
The company plans to launch new products and new versions of
existing products in new markets this year.
Tjiptono said the launch of a new version of the company's
Claritine, a widely-used non-sedative antihistamine, in the next
few months was expected to push up this year's sales.
Tjiptono said he was optimistic that sales of Claritine would
increase following a recent announcement by the U.S. Food and
Drugs Administration office to withdraw Seldane and Seldane D,
two brands of antihistamines which are said to cause serious
side-effects.
Other products manufactured by the company include hepatitis
medication, injectable antibiotics and dermatology products. (02)